HT007 Inhibitors
HT007 Inhibitors influence a variety of biochemical and cellular pathways to exert their inhibitory effect on HT007. Rapamycin, by forming a complex with FKBP12, inhibits mTOR, potentially affecting HT007 if its activity is associated with mTOR-regulated pathways. Similarly, LY294002 and Wortmannin directly target PI3K, leading to decreased phosphorylation of AKT, which can diminish HT007 activity if it is AKT-dependent. Triciribine, by inhibiting AKT activation, can also reduce HT007 function if HT007 relies on AKT for its activity.
Furthermore, U0126 and PD98059 disrupt the MAPK/ERK pathway, potentially leading to reduced HT007 function if it depends on ERK for its activity. SP600125 and SB203580 inhibit JNK and p38 MAPK, respectively, which can lead to decreased HT007 activity if HT007 operates within these pathways.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin forms a complex with FKBP12 that binds to and inhibits mTOR, a protein kinase involved in cell growth and proliferation. Inhibition of mTOR signaling can indirectly lead to decreased activity of HT007 if HT007 is involved in energy sensing or nutrient-dependent pathways regulated by mTOR. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a PI3K inhibitor that blocks the phosphatidylinositol 3-kinase pathway, leading to downregulation of AKT phosphorylation. If HT007 activity is dependent on AKT signaling for membrane localization or function, LY294002 would lead to its functional inhibition. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is a potent and irreversible PI3K inhibitor, which suppresses AKT phosphorylation and activation. By inhibiting this pathway, HT007 activity can be indirectly reduced if it relies on PI3K/AKT-mediated signaling for its stabilization or activity. | ||||||
Triciribine | 35943-35-2 | sc-200661 sc-200661A | 1 mg 5 mg | $102.00 $138.00 | 14 | |
Triciribine specifically inhibits the activation of AKT without affecting PI3K or mTOR. This would lead to reduced activity of HT007 if its function is AKT-dependent, particularly in pathways related to cell survival and metabolism. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 is an inhibitor of MEK1/2, which interrupts the MAPK/ERK pathway. If HT007 is regulated by ERK signaling, for instance, if ERK-mediated phosphorylation is necessary for HT007's activity, its inhibition would result in decreased function of HT007. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 is another MEK inhibitor that blocks the MAPK/ERK pathway. Its action would diminish HT007's activity if HT007 requires ERK-driven processes such as phosphorylation or localization within the cell. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of JNK, which modulates cellular processes including apoptosis and differentiation. If HT007 operates within JNK-regulated pathways or its stability is influenced by JNK activity, its function would be inhibited as a result. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is a specific inhibitor of p38 MAPK. This inhibition can lead to a decrease in HT007 activity if HT007 is part of the cellular response to stress stimuli that typically activate p38 MAPK pathways. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $92.00 $223.00 | 30 | |
PP2 is an Src family kinase inhibitor, which could lead to reduced HT007 activity if HT007 is involved in signaling cascades that are initiated by Src kinase activity, such as cell adhesion or migration. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $47.00 $145.00 | 51 | |
Dasatinib is a broad-spectrum tyrosine kinase inhibitor with activity against Src family kinases. Its inhibition of these kinases can result in decreased HT007 activity if HT007's function is contingent on tyrosine kinase signaling pathways. | ||||||